The CardioVascular Thoracic Institute (CVTI) at Keck Medicine of USC in Los Angeles offers a full range of programs and services to address cardiovascular concerns. We offer state-of-the-art screenings, diagnostic tests, innovative non-invasive treatments and specialized therapies including transplant surgery. Whatever the level of care you require, our team will design and implement the health plan that works best for you.

At the CVTI, we are pushing the boundaries of our field. We are exploring new methods to better treat our patients, including the development and refinement of new technologies. Innovative robotic therapy and heart valve replacements are just two examples of treatments that our surgeons have helped to perfect.

To treat cardiovascular and thoracic disease, medicine is shifting toward organ-based therapies and an interdisciplinary model, so that expertise from a variety of fields can be shared. This progressive model forms the basis of our patient care delivery. Our cardiologists no longer hand off cases to our cardiac surgeons. Instead, medical and surgical experts collaborate in planning the treatment and follow-up care for their patients, making the best decisions possible and using the best therapies available.

According to the American Heart Association, one in three American adults has some form of cardiovascular disease–high blood pressure, coronary heart disease, heart failure, stroke or congenital cardiovascular defects.

Heart disease is the leading cause of death in the United States for both men and women and for all racial and ethnic groups. Each year, 1.5 million Americans suffer heart attacks – and one-third of those are fatal. Each day, nearly 2,500 Americans die of cardiovascular disease.

At the CVTI, we are dedicated to improving these statistics. Our physicians offer advanced, patient-centered care to individuals whose health is threatened by cardiovascular disease, while our scientists are pursuing research that will lead to more effective treatment and prevention therapies.